Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature

Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant

Lupin appoints Claus Jepsen as President, Global Specialty

Lupin launches first generic of Pred Forte in US

Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte

Wockhardt files fast-acting Insulin Aspart injection with DCGI

The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players

India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh

We now rank 3rd in pharmaceutical production by volume and 14th by value

DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia

DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia

Lupin and Scope sign agreement for commercialization of Optase in Mexico

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome